HomeInvestors & MediaNews
- Under the agreement, 175,079 common shares will be issued at KRW 125,900 won per share, raising a total of KRW 22 billion won
- The funds will be invested in the research and development of ABL Bio’s core technologies, including the expansion of indications for its Grabody Platform
Seoul (South Korea) – November 14, 2025, ABL Bio (CEO Sang Hoon Lee), a company specializing in bispecific antibodies, today announced that ABL Bio has entered into an equity investment agreement worth KRW 22 billion won with Eli Lilly and Company (“Lilly”).
ABL Bio will issue 175,079 common shares to Lilly. The issue price is KRW 125,900 won per share, which was calculated in accordance with the regulations on the issuance and disclosure of securities. The payment date is expected to occur following the receipt of U.S. Hart-Scott-Rodino Antitrust Improvements Act (HSR Act) approval and the completion of relevant administrative procedures. The newly issued common shares will be subject to a one-year lock-up through the Korea Securities Depository.
ABL Bio plans to use the investment proceeds to advance its core technologies, including its Grabody Platform and bispecific ADCs. Through this initiative, ABL Bio aims to strengthen its drug development capabilities and, from a long-term perspective, explore a broad range of collaborative opportunities with Lilly to develop therapies.
Sang Hoon Lee, CEO of ABL Bio, said “We are very pleased to secure a strategic equity investment following our license agreement with Lilly, a global leader in innovative drug development. ABL Bio plans to expand the indications of its Grabody Platform into areas of high unmet medical need, such as obesity and muscle diseases. We expect that this collaboration with Lilly will serve as an important milestone in delivering innovative treatment options to patients worldwide”
Meanwhile, ABL Bio entered license, research and collaboration agreement with Lilly valued at up to $2.602 billion, which includes an upfront payment of $40 million. Under this agreement, both companies will collaborate to develop multiple therapeutics across modalities & therapeutic areas utilizing the Grabody Platform.
About ABL Bio
ABL Bio is developing various clinical and non-clinical assets based on its bispecific antibody platform ‘Grabody’. Clinical projects for 8 pipelines, including ABL301 (SAR446159), ABL001 (tovecimig), ABL111 (givastomig), ABL503 (ragistomig), ABL105 (YH32367), ABL104 (YH32364), ABL202, and ABL103, are underway for different indications in various countries, including the United States, China, Australia, and Korea. Currently, ABL Bio and Sanofi are in the process of transferring the clinical trial sponsorship of ABL301 (SAR446159) to Sanofi to conduct following clinical studies. ABL001 (tovecimig) has received Fast Track designation by the U.S. Food and Drug Administration (FDA). In addition, ABL111 (givastomig), co-developed with NovaBridge, has presented encouraging data from the Phase 1b clinical trial evaluating the triple combination therapy with nivolumab and chemotherapy in ESMO GI 2025. In addition, ABL Bio is continuously researching and developing several other product candidates, including bispecific antibody-drug conjugates (ADCs).